Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
August 2, 2018Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing the acebilustat Phase 3 clinical program
More »
Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
January 4, 2018Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
More »
Milestone Pharmaceuticals Appoints Lorenz Muller as Chief Commercial Officer
October 24, 2017Milestone Pharmaceuticals USA, Inc., a clinical stage cardiovascular company, today announced the appointment of Lorenz Muller as Chief Commercial Officer.
More »